We don’t just work on behalf of patients, we work with them. Through clinical trials for our investigational medicine, maralixibat, patients and their families play an integral role in helping us evaluate the drug and obtain the evidence we need for regulatory approval in the U.S. and beyond.
We initiated the Phase 3 MARCH study of maralixibat in children with PFIC in July 2019. We are in discussions with regulatory agencies with respect to the adequacy of our existing data to support regulatory submissions of maralixibat for the treatment of pruritus associated with ALGS in children. For more information about how to enroll in our clinical trials, please contact us at firstname.lastname@example.org.